Site search

Clear filter
2898 results for '' found
A Randomized, Controlled Phase 3 Study of Pacritinib Versus Physician’s Choice in Patients with Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post Essential Thrombocythemia Myel
A Randomized, Controlled Phase 3 Study of Pacritinib Versus Physician’s Choice in Patients with Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post Essential Thrombocythemia Myel
/
ORganoId GuIded N-of-1 (ORIGIN-1) trial (ACTRN12623001136695)
ORganoId GuIded N-of-1 (ORIGIN-1) trial (ACTRN12623001136695)
/
A Multicentre, Randomised, Double-Blind, Parallel-Group, Placebo-Controlled Phase 3 Efficacy and Safety Study of Benralizumab in Patients with Eosinophilic Chronic Rhinosinusitis with Nasal Polyp
/
Optimal Personalised Treatment of early breast cancer using Multi-parameter Analysis (ISRCTN42400492)
Optimal Personalised Treatment of early breast cancer using Multi-parameter Analysis (ISRCTN42400492)
/
A Phase 3, open-label, randomized study to compare the efficacy and safety of Odronextamab [REGN1979], an Anti-CD20 X Anti-CD3 bispecific antibody, versus investigators choice in previously untre
A Phase 3, open-label, randomized study to compare the efficacy and safety of Odronextamab [REGN1979], an Anti-CD20 X Anti-CD3 bispecific antibody, versus investigators choice in previously untre
/
A multicenter, international, randomized, placebo controlled, double-blind, parallel group and event driven Phase 3 study of the oral FXIa inhibitor asundexian (BAY 2433334) for the prevention of
A multicenter, international, randomized, placebo controlled, double-blind, parallel group and event driven Phase 3 study of the oral FXIa inhibitor asundexian (BAY 2433334) for the prevention of
/
A multicenter, international, randomized, active comparator-controlled, double-blind, double-dummy, parallel-group, 2-arm, Phase 3 study to compare the efficacy and safety of the oral FXIa inhibi
/
A Phase III, adjudicator-blinded, randomised study to evaluate the efficacy and safety of treatment with olorofim versus treatment with AmBisome® followed by standard of care (SOC) in patients wi
A Phase III, adjudicator-blinded, randomised study to evaluate the efficacy and safety of treatment with olorofim versus treatment with AmBisome® followed by standard of care (SOC) in patients wi
/
Effect of Nasal High-Flow Oxygen Therapy on Patient-Centred Outcomes in Patients at High Risk of Postoperative Pulmonary Complications After Cardiac Surgery: A Multicentre Randomised Controlled T
Effect of Nasal High-Flow Oxygen Therapy on Patient-Centred Outcomes in Patients at High Risk of Postoperative Pulmonary Complications After Cardiac Surgery: A Multicentre Randomised Controlled T
/
Efficacy and safety investigation of NNC0194-0499 co-administered with semaglutide in subjects with non-alcoholic steatohepatitis: a dose-ranging, placebo-controlled trial (NCT05016882)
Efficacy and safety investigation of NNC0194-0499 co-administered with semaglutide in subjects with non-alcoholic steatohepatitis: a dose-ranging, placebo-controlled trial (NCT05016882)
/
28 29 30 31 32